| Name | Title | Contact Details |
|---|
Biospec Products is a Bartlesville, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.
Nemus Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. NEMUS Bioscience Inc. is developing a novel and proprietary class of product candidates that are designed to target the body`s nervous and immune systems without inducing many of the undesirable side effects typically associated with currently available therapeutics. NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS. To become a leading developer of cannabis-based therapeutics to address unmet medical needs on a global basis.
Teewinot Life Sciences is a global biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids. Teewinot has developed patent protected processes for production of pure cannabinoids by means of biocatalysis and synthetic biology. Teewinot has also developed patent protected cannabinoid formulation technology all with the goal of improving human therapies. Headquartered in Tampa, Florida, Teewinot manufactures and licenses technology to make cost-effective and pharmaceutically pure cannabinoids. We are an industry leader in support of advancing medical research and product development. Teewinot`s global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid-based medicines.